GLP-1 Drugs May Improve Breast Cancer Outcomes
Medically reviewed by Drugs.com
via HealthDayWEDNESDAY, May 13, 2026 — Popular GLP-1 medications may be linked to better long-term outcomes for some breast cancer patients.
Previous research has shown breast cancer survivors with obesity or type 2 diabetes often experience poorer survival.
In a study published May 11 in JAMA Network Open, a team of scientists reviewed health records from nearly 8,000 patients diagnosed with breast cancer between 2006 and 2023.
The researchers compared outcomes in patients with obesity who were using GLP-1 drugs before and after diagnosis versus nonusers, and patients with type 2 diabetes using GLP-1s versus other medications, including insulin and metformin.
The study linked GLP-1 use to a lower overall risk of death from any cause over a 10-year follow-up period.
Survivors using GLP-1 medications for diabetes or obesity also had a significantly lower risk of their cancer returning after treatment.
"This study suggests that GLP-1 drugs may offer protective benefits, potentially improving survival and recurrence risk in some female patients with breast cancer," said senior author Bernard Fuemmeler, director for population sciences at the VCU Massey Comprehensive Cancer Center in Richmond, Virginia.
But, he added, more work is needed to determine whether the benefits are tied to weight control, improved heart health or other biological factors.
Researchers plan to continue their study through randomized clinical trials.
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2026-05-13 21:24
Read more
- Every 1,000 Steps After Surgery Cuts Complication Risk, Study Finds
- High-Intensity Exercise After Breast Cancer Surgery Helps Speed Recovery
- First Gene Therapy for Genetic Hearing Loss, Otarmeni, Gains FDA Approval
- ESCMID: Treatment Failure Does Not Differ Between Amoxicillin, Amoxicillin-Clavulanate for Acute Sinusitis
- Sex- and Race-Based Disparities Seen in Provider Diagnosis of Irritable Bowel Syndrome
- FDA Approves Ocrevus for Relapsing-Remitting Multiple Sclerosis In Pediatric Patients 10 Years of Age And Older
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions